A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

Pfizer has shared positive survival results from a late-stage study of its Braftovi (encorafenib) regimen in patients with ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

“These unprecedented results from the BREAKWATER trial further establish the benefit of the BRAFTOVI combination regimen and its potential to become a new standard-of-care, building on Pfizer ...

Patients who received the Pfizer drug Braftovi alongside standard of care colorectal cancer therapies had a 51% lower risk of dying than patients treated with the standard of care chemotherapy.

Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy. | Pfizer's Braftovi, combined with Eli Lilly's Erbitux and chemo, won an ...

Pfizer's BRAFTOVI combo cut death risk by 51% and more than doubled survival in BRAF-mutant colorectal cancer in a Phase 3 ...

The world’s largest meeting on cancer research has brought promising updates on treatment and prevention for colorectal ...

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with ...